Pluslife MiniDock MTB Brings Near-POC TB Testing Closer to Patients

Near point-of-care TB testing is moving from evidence to implementation, and Pluslife is proud to be part of this momentum.

On 5 May 2026, The Union TB Scientific Section opened its 2026 webinar series with a timely discussion on advancing TB screening and diagnosis in a constrained financing environment.

The session highlighted WHO's recent recommendation on near point-of-care molecular assays, the role of sputum and tongue swab testing in expanding access, and real-world lessons on bringing molecular diagnosis closer to patients.

As the first product in this new near-POC molecular TB testing class discussed during the webinar, the Pluslife MiniDock MTB platform is designed to support fast, accessible, and decentralized TB diagnosis in peripheral and resource-limited settings.

With a compact system, simplified workflow, and flexible sample options, Pluslife MiniDock MTB helps bring high-quality molecular testing closer to the point of need, supporting programs that are working to close persistent gaps in TB detection.

Pluslife remains committed to advancing affordable, practical, and scalable near-POC TB diagnostic solutions for communities that need better access to testing.